Loading…

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus

Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumi...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-07, Vol.18 (7), p.e0288271
Main Authors: Oey, Abbie, McClure, Matthew, Symons, Julian A, Chanda, Sushmita, Fry, John, Smith, Patrick F, Luciani, Kathia, Fayon, Michael, Chokephaibulkit, Kulkanya, Uppala, Rattapon, Bernatoniene, Jolanta, Furuno, Kenji, Stanley, Thorsten, Huntjens, Dymphy, Witek, James
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safety, pharmacokinetics, and pharmacodynamics of lumicitabine in infants/neonates hospitalized with RSV. In the phase 1b study, infants ([greater than or equal to]1 to [less than or equal to]12 months) and neonates (
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0288271